2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 2: Orally bioavailable compounds

2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 2: Orally bioavailable compounds 2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 1: Discovery of CB2 receptor selective compounds Discovery and Optimization of a Novel Series ofN-Arylamide Oxadiazoles as Potent, Highly Selective and Orally Bioavailable Cannabinoid Receptor 2 (CB₂) Agonists Two distinct classes of novel pyrazolinecarboxamides as potent cannabinoid CB1 receptor agonists Discovery and optimization of novel purines as potent and selective CB2 agonists Tricyclic pyrazoles part 7. Discovery of potent and selective dihydrothienocyclopentapyrazole derived CB2 ligands Discovery of potent and orally bioavailable heterocycle-based cannabinoid CB1 receptor agonists Selective Cannabinoid Receptor Type 2 (CB2) Agonists: Optimization of a Series of Purines Leading to the Identification of a Clinical Candidate for the Treatment of Osteoarthritic Pain Novel benzimidazole derivatives as selective CB2 agonists New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists